Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Vigano S, Alatzoglou D, Irving M, Ménétrier-Caux C, Caux C, Romero P, Coukos G.

Front Immunol. 2019 Jun 6;10:925. doi: 10.3389/fimmu.2019.00925. eCollection 2019. Review.

2.

Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.

Ebrahimi-Nik H, Michaux J, Corwin WL, Keller GL, Shcheglova T, Pak H, Coukos G, Baker BM, Mandoiu II, Bassani-Sternberg M, Srivastava PK.

JCI Insight. 2019 Jun 20;5. pii: 129152. doi: 10.1172/jci.insight.129152.

3.

18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.

Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V, Peters S, Krueger T, de Leval L, Kandalaft LE, Nicod-Lalonde M, Romero P, Prior JO, Coukos G, Schaefer N.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1859-1868. doi: 10.1007/s00259-019-04348-x. Epub 2019 Jun 18.

PMID:
31214790
4.

Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice.

Cicone F, Gnesin S, Denoël T, Stora T, van der Meulen NP, Müller C, Vermeulen C, Benešová M, Köster U, Johnston K, Amato E, Auditore L, Coukos G, Stabin M, Schaefer N, Viertl D, Prior JO.

EJNMMI Res. 2019 Jun 11;9(1):53. doi: 10.1186/s13550-019-0524-7.

5.

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.

Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, Conejo-Garcia J, Ramay HR, Montone KT, Powell DJ Jr, Gimotty PA, Facciabene A, Jackson DG, Weber JS, Rodig SJ, Hodi SF, Kandalaft LE, Irving M, Zhang L, Foukas P, Rusakiewicz S, Delorenzi M, Coukos G.

Cancer Cell. 2019 Jun 10;35(6):885-900.e10. doi: 10.1016/j.ccell.2019.05.004.

PMID:
31185212
6.

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M.

Nat Rev Clin Oncol. 2019 May 15. doi: 10.1038/s41571-019-0218-0. [Epub ahead of print] Review.

PMID:
31092901
7.

[Side effects of immune checkpoint inhibitors: diagnosis and management].

Perrinjaquet C, Zaher M, Ferraro DA, Comte D, Trueb L, Zimmermann S, Coukos G, Orcurto A.

Rev Med Suisse. 2019 May 15;15(651):1010-1016. French.

PMID:
31091034
8.

High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.

Costa-Nunes C, Cachot A, Bobisse S, Arnaud M, Genolet R, Baumgaertner P, Speiser DE, Sousa Alves PM, Sandoval F, Adotévi O, Reith W, Protti MP, Coukos G, Harari A, Romero P, Jandus C.

Clin Cancer Res. 2019 Apr 23. doi: 10.1158/1078-0432.CCR-18-1356. [Epub ahead of print]

PMID:
31015344
9.

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.

Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, Teijeira A, Kandalaft LE, Romero P, Coukos G, Neyns B, Sancho D, Melero I, de Vries IJM.

J Immunother Cancer. 2019 Apr 18;7(1):109. doi: 10.1186/s40425-019-0580-6. Review.

10.

Going Beyond the Sequences: TCR Binding Patterns at the Service of Cancer Detection.

Zoete V, Coukos G.

Cancer Res. 2019 Apr 1;79(7):1299-1301. doi: 10.1158/0008-5472.CAN-19-0225.

PMID:
30936076
11.

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Apr;120(8):870. doi: 10.1038/s41416-019-0425-6.

12.

Computational KIR copy number discovery reveals interaction between inhibitory receptor burden and survival.

Pyke RM, Genolet R, Harari A, Coukos G, Gfeller D, Carter H.

Pac Symp Biocomput. 2019;24:148-159.

13.

The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.

Vannini N, Campos V, Girotra M, Trachsel V, Rojas-Sutterlin S, Tratwal J, Ragusa S, Stefanidis E, Ryu D, Rainer PY, Nikitin G, Giger S, Li TY, Semilietof A, Oggier A, Yersin Y, Tauzin L, Pirinen E, Cheng WC, Ratajczak J, Canto C, Ehrbar M, Sizzano F, Petrova TV, Vanhecke D, Zhang L, Romero P, Nahimana A, Cherix S, Duchosal MA, Ho PC, Deplancke B, Coukos G, Auwerx J, Lutolf MP, Naveiras O.

Cell Stem Cell. 2019 Mar 7;24(3):405-418.e7. doi: 10.1016/j.stem.2019.02.012.

PMID:
30849366
14.

Tumor Landscapes: β-Catenin Drives Immune Desertification.

Dangaj D, Barras D, Coukos G.

Clin Cancer Res. 2019 May 15;25(10):2943-2945. doi: 10.1158/1078-0432.CCR-19-0188. Epub 2019 Mar 5.

PMID:
30837277
15.

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Feb;120(4):424-434. doi: 10.1038/s41416-019-0384-y. Epub 2019 Feb 5. Erratum in: Br J Cancer. 2019 Apr;120(8):870.

PMID:
30718808
16.

Safety and Tolerability of Adoptive Cell Therapy in Cancer.

Wolf B, Zimmermann S, Arber C, Irving M, Trueb L, Coukos G.

Drug Saf. 2019 Feb;42(2):315-334. doi: 10.1007/s40264-018-0779-3. Review.

PMID:
30649750
17.

[Recent advances and future directions in CAR-T cell therapy in pediatric oncology].

Ceppi F, Renella R, Diezi M, Ansari M, Duchosal MA, Arber C, Kandalaft L, Coukos G, Beck-Popovic M.

Rev Med Suisse. 2019 Jan 9;15(N° 632-633):85-91. Review. French.

PMID:
30629377
18.

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.

Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M.

Lancet Oncol. 2019 Jan;20(1):e54-e64. doi: 10.1016/S1470-2045(18)30828-3.

PMID:
30614479
19.

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.

Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M.

J Immunother Cancer. 2018 Dec 27;6(1):156. doi: 10.1186/s40425-018-0481-0.

20.

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.

Maio M, Coukos G, Ferrone S, Fox BA, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, Rüttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R.

Cancer Immunol Immunother. 2019 Jan;68(1):1-9. doi: 10.1007/s00262-018-2285-y. Epub 2018 Dec 18.

PMID:
30564889
21.

The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.

Gfeller D, Guillaume P, Michaux J, Pak HS, Daniel RT, Racle J, Coukos G, Bassani-Sternberg M.

J Immunol. 2018 Dec 15;201(12):3705-3716. doi: 10.4049/jimmunol.1800914. Epub 2018 Nov 14.

PMID:
30429286
22.

A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.

Ghosn J, Vicino A, Michielin O, Coukos G, Kuntzer T, Obeid M.

J Immunother Cancer. 2018 Oct 22;6(1):110. doi: 10.1186/s40425-018-0429-4.

23.

Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor.

Soler M, Li X, John-Herpin A, Schmidt J, Coukos G, Altug H.

ACS Sens. 2018 Nov 26;3(11):2286-2295. doi: 10.1021/acssensors.8b00523. Epub 2018 Oct 19.

PMID:
30339020
24.

50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.

Herrera FG, Valerio M, Berthold D, Tawadros T, Meuwly JY, Vallet V, Baumgartner P, Thierry AC, De Bari B, Jichlinski P, Kandalaft L, Coukos G, Harari A, Bourhis J.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):320-334. doi: 10.1016/j.ijrobp.2018.09.023. Epub 2018 Sep 27.

25.

Correction to: CART cells are prone to Fas- and DR5-mediated cell death.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A.

J Immunother Cancer. 2018 Sep 25;6(1):92. doi: 10.1186/s40425-018-0410-2.

26.

Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches.

Digklia A, Duran R, Homicsko K, Kandalaft LE, Hocquelet A, Orcurto A, Coukos G, Denys A.

Cardiovasc Intervent Radiol. 2018 Sep 12. doi: 10.1007/s00270-018-2074-1. [Epub ahead of print]

PMID:
30209564
27.

Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome.

Mylonas R, Beer I, Iseli C, Chong C, Pak HS, Gfeller D, Coukos G, Xenarios I, Müller M, Bassani-Sternberg M.

Mol Cell Proteomics. 2018 Dec;17(12):2347-2357. doi: 10.1074/mcp.RA118.000877. Epub 2018 Aug 31.

28.

CART cells are prone to Fas- and DR5-mediated cell death.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A.

J Immunother Cancer. 2018 Jul 13;6(1):71. doi: 10.1186/s40425-018-0385-z. Erratum in: J Immunother Cancer. 2018 Sep 25;6(1):92.

29.

Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network.

Grass F, Martin D, Montemurro M, Mathevet P, Wolfer A, Coukos G, Demartines N, Hübner M.

Chemotherapy. 2018;63(3):143-147. doi: 10.1159/000488774. Epub 2018 Jun 13.

PMID:
29898438
30.

Label-Free Optofluidic Nanobiosensor Enables Real-Time Analysis of Single-Cell Cytokine Secretion.

Li X, Soler M, Szydzik C, Khoshmanesh K, Schmidt J, Coukos G, Mitchell A, Altug H.

Small. 2018 Jun;14(26):e1800698. doi: 10.1002/smll.201800698. Epub 2018 May 28.

PMID:
29806234
31.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 Aug;21(3):425-532. doi: 10.1007/s10456-018-9613-x. Review.

32.

The C-terminal extension landscape of naturally presented HLA-I ligands.

Guillaume P, Picaud S, Baumgaertner P, Montandon N, Schmidt J, Speiser DE, Coukos G, Bassani-Sternberg M, Filippakopoulos P, Gfeller D.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):5083-5088. doi: 10.1073/pnas.1717277115. Epub 2018 Apr 30.

33.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
34.

T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan3311. doi: 10.1126/scitranslmed.aan3311.

35.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.

Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.

36.

Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.

Yuan X, Yang M, Chen X, Zhang X, Sukhadia S, Musolino N, Bao H, Chen T, Xu C, Wang Q, Santoro S, Ricklin D, Hu J, Lin R, Yang W, Li Z, Qin W, Zhao A, Scholler N, Coukos G.

Cancer Immunol Immunother. 2018 Feb;67(2):329-339. doi: 10.1007/s00262-017-2101-0.

PMID:
29313073
37.

Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.

Guo Y, Hu J, Wang Y, Peng X, Min J, Wang J, Matthaiou E, Cheng Y, Sun K, Tong X, Fan Y, Zhang PJ, Kandalaft LE, Irving M, Coukos G, Li C.

Eur J Cancer. 2018 Feb;90:111-121. doi: 10.1016/j.ejca.2017.10.035. Epub 2018 Jan 4.

PMID:
29304474
38.

Immune-related adverse events of immune checkpoint inhibitors and the impact of sex-what we know and what we need to learn.

Özdemir BC, Coukos G, Wagner AD.

Ann Oncol. 2018 Apr 1;29(4):1067. doi: 10.1093/annonc/mdx818. No abstract available.

PMID:
29300807
39.

Cancer immunotherapy full speed ahead.

Melero I, Navarro B, Teijeira A, Coukos G.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii1-xii2. doi: 10.1093/annonc/mdx739. No abstract available.

PMID:
29253117
40.

High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.

Chong C, Marino F, Pak H, Racle J, Daniel RT, Müller M, Gfeller D, Coukos G, Bassani-Sternberg M.

Mol Cell Proteomics. 2018 Mar;17(3):533-548. doi: 10.1074/mcp.TIR117.000383. Epub 2017 Dec 14.

41.

'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.

Müller M, Gfeller D, Coukos G, Bassani-Sternberg M.

Front Immunol. 2017 Oct 20;8:1367. doi: 10.3389/fimmu.2017.01367. eCollection 2017.

42.

Mechanisms regulating T-cell infiltration and activity in solid tumors.

Lanitis E, Dangaj D, Irving M, Coukos G.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii18-xii32. doi: 10.1093/annonc/mdx238.

PMID:
29045511
43.

Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.

Facciabene A, De Sanctis F, Pierini S, Reis ES, Balint K, Facciponte J, Rueter J, Kagabu M, Magotti P, Lanitis E, DeAngelis RA, Buckanovich RJ, Song WC, Lambris JD, Coukos G.

Oncoimmunology. 2017 Jun 8;6(9):e1326442. doi: 10.1080/2162402X.2017.1326442. eCollection 2017.

44.

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.

Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclément C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derré L, Jandus C.

Nat Commun. 2017 Sep 19;8(1):593. doi: 10.1038/s41467-017-00678-2.

45.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
46.

Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.

Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon PO, Kandalaft LE, Coukos G, Gfeller D.

PLoS Comput Biol. 2017 Aug 23;13(8):e1005725. doi: 10.1371/journal.pcbi.1005725. eCollection 2017 Aug.

47.

Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven iterative survival analysis.

Crespo I, Götz L, Liechti R, Coukos G, Doucey MA, Xenarios I.

NPJ Syst Biol Appl. 2016 Dec 22;2:16037. doi: 10.1038/npjsba.2016.37. eCollection 2016.

48.

The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β2-Microglobulin through Distinct Binding Sites.

Merkle PS, Irving M, Hongjian S, Ferber M, Jørgensen TJD, Scholten K, Luescher I, Coukos G, Zoete V, Cuendet MA, Michielin O, Rand KD.

Biochemistry. 2017 Aug 1;56(30):3945-3961. doi: 10.1021/acs.biochem.7b00385. Epub 2017 Jul 19.

PMID:
28671821
49.

In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.

Schmidt J, Guillaume P, Dojcinovic D, Karbach J, Coukos G, Luescher I.

J Biol Chem. 2017 Jul 14;292(28):11840-11849. doi: 10.1074/jbc.M117.789511. Epub 2017 May 23.

50.

TIE-2 expressing monocytes in human cancers.

Turrini R, Pabois A, Xenarios I, Coukos G, Delaloye JF, Doucey MA.

Oncoimmunology. 2017 Mar 16;6(4):e1303585. doi: 10.1080/2162402X.2017.1303585. eCollection 2017.

Supplemental Content

Loading ...
Support Center